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Key Points
• For patients in developing
countries with APL, a clinical
network of institutions made it
possible to reduce
significantly the early mortality
and improve the OS.
Thanks to modern treatment with all-trans retinoic acid and chemotherapy, acute
promyelocytic leukemia (APL) is now the most curable type of leukemia. However, this
progress has not yielded equivalent benefit in developing countries. The International
Consortium on Acute Promyelocytic Leukemia (IC-APL) was established to create
a network of institutions in developing countries that would exchange experience and
data and receive support from well-established US and European cooperative groups.
The IC-APL formulated expeditious diagnostic, treatment, and supportive guidelines
that were adapted to local circumstances. APL was chosen as a model disease
because of the potential impact on improved diagnosis and treatment. The project
included 4 national coordinators and reference laboratories, common clinical record forms, 5 subcommittees, and laboratory and
data management training programs. In addition, participating institutions held regular virtual and face-to-face meetings. Complete
hematological remission was achieved in 153/180 (85%) patients and 27 (15%) died during induction. After a median follow-up of 28
months, the 2-year cumulative incidence of relapse, overall survival (OS), and disease-free survival (DFS) were 4.5%, 80%, and 91%,
respectively. The establishment of the IC-APL network resulted in a decrease of almost 50% in early mortality and an improvement
in OS of almost 30% compared with historical controls, resulting in OS and DFS similar to those reported in developed countries.
(Blood. 2013;121(11):1935-1943)
Introduction
All-trans retinoic acid (ATRA) in combination with anthracycline-
based chemotherapy constitutes the mainstay of modern strate-
gies for the treatment of patients with newly diagnosed acute
promyelocytic leukemia (APL).1-3 Contemporary clinical trials
have reported complete remission (CR) and long-term disease-free
survival (DFS) rates of approximately 90% and 85%, respectively.3-11
The major cause of treatment failure is death during induction
therapy. This ranged from 5% to 10% in recent multicenter
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trials;3,4,6,8,11,12 most deaths were the result of hemorrhage,
infection, and differentiation syndrome (DS).
Unfortunately, the treatment outcome for patients in developing
countries with APL is signiﬁcantly inferior compared with that
reported in Europe and United States. A retrospective analysis of
134 Brazilian patients with APL reported a death rate of 32%
during induction and 10% during consolidation.13 This is in
contrast with results from trials conducted in developed countries,
where these rates of death during induction ranged from 5% to 10%
and were , 5% during consolidation, respectively.3,4,6,8,12 Conse-
quently, the reported long-term overall survival (OS) is ,60% in
developing countries.13 An important feature is that most of the
deaths that occur during induction are caused by hemorrhage.
Therefore, APL-associated coagulopathy is a particularly relevant
target for medical education programs because it may be counter-
acted by early administration of ATRA and by rapid initiation of
supportive measures.1,14
The International Consortium on Acute Promyelocytic Leuke-
mia (IC-APL) was established in 2005 as an initiative of the
International Members Committee of the American Society of
Hematology. The purpose was to create a network of institutions in
developing countries that would exchange experience and data and
receive support from well-established cooperative groups in the
United States and Europe. The IC-APL formulated treatment
guidelines based on protocols from successful clinical trials3 in
developing countries and adapted them to local conditions and
resources. These guidelines covered standardized approaches for
speciﬁc and prompt diagnosis, treatment, supportive care, and
disease follow-up measures. Here we demonstrate that by using
limited resources, it is possible to reduce the gap between developed
and developing countries regarding the quality of care and treatment
outcome in APL.
Methods
Eligibility of countries to participate in the IC-APL
In order to participate in the IC-APL, countries had to fulﬁll minimum
requirements. These included availability of principle drugs scheduled in
the IC-APL protocol, preexisting transfusion medicine services that could
guarantee adequate availability of platelets and other blood derivatives,
a hematology laboratory capable of performing basic ﬂuorescence micros-
copy, the ability to report data and participate in meetings using web-based
tools, and identiﬁcation of 1 national coordinator and 1 person responsible
for molecular studies. Brazil, Mexico, Chile, and Uruguay were selected as
participating countries.
Eligibility of patients
Adult patients (age 15 to 75 years) in whom the diagnosis of APL was
suspected underwent bone marrow (BM) aspiration followed by immuno-
ﬂuorescence staining using the anti-promyelocytic leukemia (anti-PML)
antibody (PG-M3).15 ATRA treatment was initiated immediately in all
cases in which the diagnosis of APL was suspected based on morphology.
The provisional diagnosis of APL was conﬁrmed using the anti-PML
immunoﬂuorescence technique, upon which daunorubicin was combined
with ATRA. Cytogenetic analysis for t(15;17) and/or polymerase chain
reaction (PCR) analyses for PML/RARA rearrangements were then
performed on BM samples; the detection of 1 or the other was required
for conﬁrmation of the diagnosis of APL and enrollment in the protocol.
Patients with de novo APL, normal hepatic and renal function, no cardiac
contraindications to anthracycline chemotherapy, and an Eastern Co-
operative Oncology Group performance status of less than 4 were eligible.
Informed consent was obtained from all patients. According to the
Declaration of Helsinki, the research ethics board of each participating
hospital approved the protocol.
Induction therapy
Induction therapy was identical to that adopted in the Programa Español
de Tratamiento en Hematologia/Dutch-Belgian Hemato-Oncology Co-
operative Group Leucemia Promielocı´tica Aguda (PETHEMA/HOVON
LPA) 2005 trial,3 except that idarubicin (12 mg/m2/d) was replaced by
daunorubicin (60 mg/m2/d) because daunorubicin was more readily
available and cost less than idarubicin in the participating countries.
Supplemental Table 1 shows the IC-APL treatment schedule. Oral
ATRA (45 mg/m2/d) was administered in 2 daily divided doses until
complete hematologic remission was achieved. Daunorubicin was given
as an intravenous bolus on days 2, 4, 6, and 8, except for patients .70
years who received only the 3 ﬁrst doses of daunorubicin. For patients
<20 years, the ATRA dose was adjusted to 25 mg/m2/d.
Postinduction therapy
Patients who achieved complete hematological remission (CR) received
3 monthly consolidation courses with ATRA and anthracycline-based
chemotherapy that was identical to that adopted in the PETHEMA/HOVON
LPA2005 trial,3 except that, as for induction, idarubicin was replaced by
daunorubicin. Consolidation therapy followed a risk-adapted strategy
according to the risk groups, as deﬁned by the PETHEMA/GIMEMA
groups.3,16 For low-risk patients, ATRA was combined with daunorubicin
(25 mg/m2 on days 1 to 4) in the ﬁrst cycle, mitoxantrone (10 mg/m2 on
days 1 to 3) in the second cycle, and daunorubicin (60 mg/m2 on day 1) in
the third cycle. For intermediate-risk patients, consolidation was intensiﬁed
by increasing the dose of daunorubicin to 35 mg/m2 in the ﬁrst cycle and
by repeating the infusion of 60 mg/m2 on the second day of the third
cycle. For high-risk patients, consolidation was further intensiﬁed
by adding cytarabine in cycles 1 (1000 mg/m2 on days 1 to 4) and 3
(150mg/m2 q8h days 1 to 4). In addition, mitoxantrone (10 mg/m2/d) was
administered for 5 days in the second cycle; the anthracyclines dosage in
cycles 1 and 3 was as described for low-risk patients. High-risk patients
.60 years did not receive cytarabine and were treated as intermediate-
risk patients. The use of ATRA and anthracycline monochemotherapy for
the treatment of elderly patients was based on the previously reported
results of the PETHEMA studies LPA96 and LPA99.17 Maintenance
therapy was identical to that used in the LPA2005 trial, as described
elsewhere.3
Anti-PML immunofluorescence staining
BM aspirates were stained with PG-M3 and analyzed as described
previously.15
Genetic confirmation of the diagnosis and monitoring of
treatment response
Pretreatment BM samples were cultured and analyzed by standard
cytogenetic methods. Samples were also tested for the presence of PML/
RARA rearrangements by reverse-transcription polymerase chain reaction
(RT-PCR) according to the BIOMED-1 guidelines in centralized
laboratories in Ribeirão Preto (Brazil, E.M.R.), Puebla (Mexico, J.G.-E.),
Santiago (Chile, M.S.U.), and Montevideo (Uruguay, M.d.R.U.).18 Treatment
response was conﬁrmed by morphological analysis and by RT-PCR at the
end of the 3 consolidation cycles. Minimal residual disease (MRD) was
monitored at national reference laboratories by RT-PCR of BM samples
obtained every 3 months during maintenance and for 2 years after completion
of treatment. Additional samples from 71 patients were also evaluated for
MRD at the end of induction and at the end of the second consolidation
cycle. RT-PCR assays were set up with a sensitivity level of 1 leukemic cell
in 1024 cells.
1936 REGO et al BLOOD, 14 MARCH 2013 x VOLUME 121, NUMBER 11
For personal use only.on June 2, 2016. by guest  www.bloodjournal.orgFrom 
Supportive measures
We followed the guidelines of the European LeukemiaNet for supportive
measures for APL patients.1 Platelets were transfused to maintain the
platelet count above 30 000 to 50 000/uL, and cryoprecipitate was
administered to maintain the ﬁbrinogen level above 150 mg/dL. DS was
diagnosed according to the presence of the following signs or symptoms, as
described by Frankel et al:19 unexplained fever, dyspnea, pleural and/or
pericardial effusion, pulmonary inﬁltrates, renal failure, hypotension, and
unexplained weight gain of .5 kg. No single sign or symptom was con-
sidered sufﬁcient to make a diagnosis of the syndrome. Patients with 4 or
more of these signs or symptoms were classiﬁed as having severe DS; those
with 2 or 3 signs or symptoms were considered to have moderate DS.
Regardless of the severity, treatment with dexamethasone at a dose of 10 mg
twice daily by intravenous injection was started at the earliest symptom or
sign of DS and maintained until the resolution of the syndrome. ATRA was
temporarily discontinued only in the setting of severe DS that led to
respiratory or renal dysfunction requiring admission to the intensive care unit.
Network structure and operation
Figure 1 illustrates how the network operated in a given case and the
geographic distribution of the centers. All cases were registered using
common clinical record forms (CRFs) in the Pediatric Oncology Network
Database (POND), which was used for online collection of clinical and
laboratory data. The 4 national coordinators periodically accessed and
analyzed the integrity of the data and the essential treatment response and
toxicity parameters of the patients enrolled in their respective countries.
Bimonthly discussions were held via virtual meetings in each country at
which a summary of the clinical evolution and laboratory and MRD results
of each case were discussed in a chat room at www.cure4kids.org. When
necessary, international experts participated in the meeting, and face-to-face
meetings with all participants were held at least twice a year. The Treatment
Guidelines Subcommittee was responsible for the study design and CRF
elaboration. To ensure that drugs were available at all times, even at the
most remote centers, the Drug Availability Subcommittee was created.
Examples of its activities include establishing a small stock of ATRA in the
Figure 1. Organization of the IC-APL network for
the diagnosis and treatment of a given case of
APL. Actions taken at the local centers are indicated in
red and those taken at the national reference labora-
tories are indicated in blue. (A) The interaction with the
panel of international experts and the educational
activities are shown in yellow. (B) Geographical distribu-
tion of the IC-APL institutions.
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emergency rooms of a few centers and submitting letters to health
authorities asking for their support. The Laboratory and Diagnostic
Guidelines Subcommittee was responsible for the standardization of
diagnostic and MRD methods as well as for the control of biobanking.
The Web Registration and Auditing Subcommittee oversaw the quality of
the data in the web database and the infrastructure for the web meetings.
Finally, a separate committee was responsible for obtaining ﬁnancial support
from private and public sources. Training on anti-PML immunoﬂuorescence
staining and data management was organized in each country, and
educational material and presentations for different audiences were created
in order to increase the awareness of APL by the medical community.
Definitions and statistical analysis
Here we report on patients who were entered into the study between June
2006 and September 2010. Patient follow-up was updated in November
2011. Molecular remission was deﬁned as the disappearance on an ethidium
bromide gel of the PML/RARA–speciﬁc band visualized at diagnosis with
the use of RT-PCR assays. Molecular persistence was deﬁned as PCR
positivity in 2 consecutive BM samples collected at the end of consolidation
therapy; molecular relapse was deﬁned as reappearance of the PML/RARA–
speciﬁc band in 2 consecutive BM samples collected 15 days apart at any
time after consolidation therapy. Patients whose partial thromboplastin time
and prothrombin time test results were abnormal were deemed to have
a coagulopathy, regardless of whether they presented with bleeding
symptoms or not. Patients were categorized according to the risk of
relapse as described elsewhere.3,16
Univariable and multivariable logistic regression analysis was performed
in order to identify prognostic factors for CR. OS, disease–free survival,
and event–free survival (EFS) were calculated using the Kaplan–Meier
method. OS was deﬁned as the time from the initiation of induction therapy
to death from any cause; those alive or lost to follow-up were censored on
the date when last known to be alive. DFS was deﬁned as the time from CR
to disease relapse or death from any cause, whichever occurred ﬁrst.
Patients who were alive without disease relapse were censored at the time
last seen alive and disease free. EFS was deﬁned as the time from the
initiation of induction therapy to disease relapse, development of secondary
malignancy, or death from any cause, whichever occurred ﬁrst. The log–rank
test was used to compare Kaplan–Meier curves. Cumulative incidence curves
for nonrelapse death and relapse with or without death were constructed
reﬂecting time to relapse and time to nonrelapse death as competing risks.20
Time to relapse and time to nonrelapse death were measured from the date of
CR. Univariable and multivariable proportional hazards (PHs) regression
analysis was performed for potential prognostic factors for overall survival.
Potential prognostic factors examined in multivariate analysis were age at
diagnosis, patient sex, white blood cell (WBC) counts, platelet counts,
hemoglobin levels, coagulopathy, French-American-British classiﬁcation,
PML breakpoint, creatinine, albumin, uric acid, ﬁbrinogen, and BM blasts.
Due to the large number of potential prognostic factors relative to the number of
events, multivariable analysis for OS was performed using the penalized PH
model.21-23 The PH assumption for each variable of interest was tested.
Linearity assumption for all continuous variables was examined in logistic and
PH models using restricted cubic spline estimates of the relationship between
the continuous variable and log relative hazard/risk. Multivariable regression
analysis for relapse, nonrelapse death, and DFS was not performed due to the
small number of events. The multiple imputation technique24-26 was used to
reduce bias due to missing data in multivariable regression analysis. All P values
are 2-sided at the signiﬁcance level of 0.05. All calculations were performed
using SAS 9.2 (SAS Institute, Cary, NC) and R 2.10.1 (the CRAN Project).
Results
Patient baseline characteristics
IC-APL–participating institutions evaluated 215 consecutive patients
in whom a diagnosis of APL was suspected were evaluated in.
Thirty-two were considered ineligible: in 15 patients, the diagnosis
of APL was not conﬁrmed by anti-PML immunoﬂuorescence and
later by (cyto)genetic testing; 4 had poor performance status; and 3
had received previous chemotherapy. In addition, for 2 patients,
ATRA or daunorubicin was not available at the institution at the
time of diagnosis, 4 patients refused to sign the informed consent, 2
patients were .75 years, and 2 patients were pregnant. Table 1
shows the baseline characteristics of the 183 patients enrolled in
the study. In Brazil, 122 patients were enrolled, along with 30 in
Mexico, 23 in Chile, and 8 in Uruguay. More patients were
enrolled in Brazilians because of the larger population at risk as
well as the larger number of participating institutions and the
longer accrual period; Chile and Uruguay joined the study 8
months after Brazil and Mexico joined.
Approximately one-third of patients had .10 3 109/L leukocytes
at diagnosis and thus were classiﬁed as high risk for relapse;
whereas only 30 (16%) patients presented with <10 3 109/L
leukocytes and .40 3 109/L platelets and were considered low
risk. Thus, the majority (52%) of patients were classiﬁed as
intermediate risk. Coagulopathy was present in 114 (62%) of the
patients at diagnosis, the median plasma level of ﬁbrinogen was
156.9 mg/dL (range: 10 to 605), and in 107 patients these levels
were <170 mg/dL. There were no signiﬁcant differences in the
distribution of patients according to risk categories or to the subtype
of PML breakpoint among the 4 countries (data not shown).
Diagnosis using anti-PML immunofluorescence technique
Immunoﬂuorescence staining of BM aspirates using PG-M3 was
performed at local institutions for 130 cases in which the diagnosis
of APL was suspected based on the morphology. For 115 patients,
this technique allowed for the rapid diagnosis of APL based on the
detection of the characteristic microspeckled pattern of PML
delocalization from nuclear bodies (supplemental Figure 1). In the
15 negative cases, the presence of the PML/RARA rearrangement
was not conﬁrmed by RT-PCR and/or cytogenetics, and the
patients were considered ineligible. Among the 115 cases with
positive PML antibody results, the presence of the PML/RARA
rearrangement was conﬁrmed by RT-PCR (n 5 59), cytogenetics
(n 5 5), or both (n 5 51). In the remaining 53 cases, APL
diagnosis was based only on cytogenetics. In 1 case, the
immunoﬂuorescence pattern was equivocal. RT-PCR showed
a PLZF-RARA fusion predicting retinoid resistance. Consequently,
this patient was not eligible for the study protocol. No false-
negative results were observed with the PML antibody test. On
average, results were available within 4 hours; results of RT-PCR
lagged by 2 or 3 days.
Induction therapy
Of the 183 patients enrolled, 3 patients who started the induction
treatment were lost to follow-up without assessment for CR and
thus were excluded in the analysis of response to induction. Of the
180 evaluable patients, 153 (85%) achieved complete hematolog-
ical remission (Table 2). The average time to achieve CR was 38
days. Twenty-seven patients (15%) died between diagnosis and
the ﬁrst morphologic evaluation of BM, which was on the thirtieth
day of treatment (early death), with death occurring in 9 cases
within the ﬁrst 7 days. The early death rate according to the
risk stratiﬁcation was 20.7%, 11.6%, and 6.7% in the high-,
intermediate-, and low-risk groups (P 5 .01), respectively. The
major causes of death were hemorrhage (13 patients, 48.1%),
infection (7, 25.9%), and DS (5, 18.5%; Table 3). Among the 13
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deaths caused by hemorrhage, 4 occurred within 7 days of diagnosis.
DS was diagnosed in 42 (23%) patients, with an associated
mortality rate of 11.9%. It should be noted that in spite of the
relatively high frequency of deaths due to infection during
induction, the median time to neutrophil recovery (absolute
neutrophil counts [ANC]. 13 109/L) was 25 days (Table 2). One
patient showed a considerable decrease of the left ventricular
ejection fraction (LVEF; 61% at diagnosis and 25% at day 23) and
received a modiﬁed consolidation treatment. The LVEF recovered
and was maintained at 50% after consolidation and maintenance
with a 15-month follow-up.
Seven of the 17 patients with APL who were deemed ineligible
died during induction with ATRA and anthracyclines (n 5 15) or
monochemotherapy with anthracycline (n5 2), and all deaths were
caused by hemorrhage. Ten patients achieved hematological CR, of
whom 2 were lost to follow-up after consolidation, 1 died of central
nervous system bleeding during consolidation, 1 relapsed after
1.8 months, and 6 survived and were in hematological remission.
Table 4 shows the univariable and multivariable logistic regression
analyses for CR. The analyses of the complete list of variables are
presented in supplemental Table 2. WBC counts and albumin levels
were signiﬁcantly associated with CR in both the univariable and
multivariable analyses. The presence of coagulopathy was signiﬁcant
only in the multivariable analysis, and the abnormal levels of
creatinine were signiﬁcant only in the univariable analysis.
Consolidation and maintenance therapy
Data regarding consolidation toxicities were available for 148 ﬁrst,
147 second, and 144 third consolidation cycles (supplemental
Table 3). Five patients did not have consolidation toxicity information:
2 died immediately after achieving hematologic remission and 3
had missing data. The most frequent hematologic toxicity was
neutropenia, which was classiﬁed as grade 4 according to the
National Comprehensive Cancer Network classiﬁcation; this lasted
.15 days in 9%, 21%, and 11% of patients in the ﬁrst, second, and
third consolidation cycles, respectively (supplemental Table 3).
Hospitalization lasting .10 days was required in 5% to 11% of the
episodes of hematologic toxicity. The frequency of hospitalization
was higher for patients in the intermediate- and high-risk groups
compared with those in the low-risk group (5% to 11%, 8% to
18%, and 34% to 51% in low-, intermediate-, and high-risk groups,
respectively; P , .001). Ten patients died in CR (Table 3), all
during consolidation; the main cause of death was infection
(8, 80%). In 1 case, the cause of death was respiratory failure, but
there was .1 cause leading to this complication. No signiﬁcant
toxicities were reported during maintenance.
Table 1. Demographic and baseline characteristics of APL patients
in the IC-APL trial
Characteristic n Median (range) n (%)
N 183 (100)
Age, y 183 34 (15–73)
,18 9 (5)
18–40 114 (62)
41–60 53 (29)
61–70 6 (3)
.70 1 (0.5)
Gender 183
Male 88 (48)
Female 95 (52)
Eastern Cooperative
Oncology Group
183 0 (0–3)
0 133 (73)
1 3 (2)
2 30 (16)
3 17(9)
Fever 183
No 86 (47)
Yes 97 (53)
WBC count, 3 109/L 183 3.6 (0.1–132)
#5 104 (57)
.5–10 21 (11)
.10–50 42 (23)
.50 16 (9)
Platelet count, 3 109/L 183 23 (1–128)
#40 140 (77)
.40 43 (23)
Relapse-risk group 183
Low 30 (16)
Intermediate 95 (52)
High 58 (32)
Hemoglobin, g/dL 183 8.6 (3.4–15.6)
#10 145 (79)
.10 38 (21)
BM blasts (%) 170 85 (3–100)
Creatinine, mg/dL 183 0.8 (0.23–2.20)
#1.4 178 (97)
.1.4 5 (3)
Uric acid, mg/dL 172 4.2 (0.8–24.3)
#7 163 (95)
.7 9 (5)
Fibrinogen, mg/dL 178 156.9 (10–605)
#170 107 (60)
.170 71 (40)
Coagulopathy
Yes 114 (62)
No 69 (38)
Albumin, g/dL 168 4 (2.2–5.3)
#3.5 43 (26)
.3.5 125 (74)
Morphologic subtype 183
Hypergranular 174 (95)
Microgranular 9 (5)
PML/RARa isoform 169
bcr1 106 (63)
bcr2 6 (3)
bcr3 57 (34)
Table 2. Induction outcome, differentiation syndrome frequency,
and severity
Characteristic Median (range) No. (%)
Overall 180* (100)
Morphologic CR 153 (85)
Days to CR 38 (14–151)
Days to polymorphonuclear (PMN)
cell count .1 3 109/L
25 (5–50)
Days to platelet counts .50 3 109/L 22 (0–51)
Symptoms/signs associated with DS
0 138 (77)
1 6 (3)
2 15 (8)
3 16 (9)
$4 5 (3)
*Three patients who were lost to follow-up were excluded in the analysis of
induction outcome.
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Treatment outcome
At the time of analysis, 75.4% of patients enrolled and 90.2% of
those achieving CR were alive; 5 (2.6%) were lost to follow-up and
10 (5.2%) died while in CR. There was 1 case of molecular
persistence of the PML/RARA rearrangement after consolidation
and 9 relapses, of which 4 were molecular relapses. Two of the 9
relapsed patients died during salvage therapy, whereas all others
achieved a second remission using alternative therapy. No
secondary malignancies were reported. The median follow-up
among survivors was 28 months (range: 7 months to 62 months).
The 2-year OS and DFS were 80% (95% conﬁdence interval [CI]:
73% to 85%] and 91% (95% CI: 86% to 95%), respectively
(Figure 2A). The 2-year cumulative incidence of relapse (CIR) was
4.5% (95% CI: 1.8% to 9.2%). The 2-year cumulative incidence of
nonrelapse mortality (CI of NRM) was 5.3% (95% CI: 2.4% to
9.6%; Figure 2B). None of the patients classiﬁed as low risk
relapsed (Table 5). In contrast, the 2-year CIR and CI of NRM
among high-risk patients was 14.1% ([95% CI: 4.6% to 28.7%]
and 10.9% [95% CI: 3.9% to 21.8%], respectively; P 5 .08 for CIR
and P 5 .04 for CI of NRM; Table 5). Furthermore, the EFS of
high-risk patients was 59% (95% CI: 45% to 72%; P 5 .005),
resulting in a signiﬁcantly lower rate of 2-year OS of 67% (P 5
.01; Table 5). Supplemental Table 4 shows the Cox proportional
hazards analysis for OS, age, WBC counts, hemoglobin levels, the
presence of coagulopathy, creatinine levels (abnormal vs normal),
and albumin levels, which were signiﬁcantly associated with OS.
Due to the small number of events, a multivariable model was
not explored for DFS analysis. In univariable analysis of DFS,
only WBC counts demonstrated a signiﬁcant association
(supplemental Table 5).
Discussion
Using APL as a model disease, we demonstrate that clinical
networking may result in signiﬁcant improvement in patient
outcome. We also show the potential to achieve treatment results in
developing countries that are comparable to those obtained in the
United States and Europe. Table 6 shows some of the problems
faced and the solutions encountered by the IC-APL network before
and during development of the study.
APL has a high cure rate in developed countries and a high
prevalence in young patients. It is therefore an ideal disease in
which to test the impact of educational measures and cooperative
networks on short- and long-term outcomes of patients in developing
countries, especially in light of its high mortality if left untreated.1
In addition, therapy is based on relatively inexpensive drugs, and
the adoption of standard supportive measures reduces the risk of
severe complications related to the disease and its treatment.1
Prior to establishment of the IC-APL, the 2-year OS of adult
patients with APL in Brazil was about 50% and the induction
mortality rate was .30%.13 Unfavorable results were also reported
among children from 7 Latin American countries.27 As a result of
the IC-APL, the 2-year OS increased to 80% and the induction
mortality rate was reduced by half. Mortality associated with DS
and infection were also reduced compared with the retrospective
analysis previously reported.13,28 However, although the observed
mortality rate for DS was similar to that reported by de Botton
et al29 in the APL93 trial, it was greater than that reported in more
recent studies using ATRA and anthracyclines.3,5,6,12 Therefore,
we believe that the need to improve the early diagnosis and treatment
of DS in the context of the IC-APL still exists.
With regard to the clinical and laboratory features at pre-
sentation, we observed no relevant differences in the present study
compared with those reported in developed countries, except for
the increased frequency of patients in the high relapse-risk
group.4,6,9 It is possible that this higher frequency reﬂects a late
diagnosis of APL due to poorer or delayed access to tertiary
specialized centers. It may also be more representative of the true
risk-group distribution. High-risk patients are less likely to be
treated in clinical trials due to the urgent need to deliver the ﬁrst
dose of anthracycline. The frequency of the breakpoint cluster region 1
(bcr1) PML/RARA isoform was not increased compared with that
reported in Europe, which contrasts with previous studies
analyzing patients from Latin America.30-32 This difference,
however, likely reﬂects the distinct geographical and ethnic origin
of patients in the 2 reported series (eg, Mexican mestizos by Santos
et al 28 and mostly Brazilian in this study).
Immunoﬂuorescence staining using the anti-PML antibody was
adopted as a rapid diagnostic method that could be performed at all
centers and did not require a sophisticated infrastructure. A central
laboratory in each participating country performed the genetic
conﬁrmation using RT-PCR, and, in all cases, both techniques
yielded concordant results. Our results corroborate those of
Dimov et al33 who estimated the sensitivity and speciﬁcity of
the immunoﬂuorescence staining test to be 98.9% and 98.7%,
respectively. More importantly, the results demonstrate the feasibility
Table 3. Causes of death during induction and while in complete
remission
Cause of death
During induction
n (%)
In complete remission
n (%)
Disease progression 1 (3.7%)
Hemorrhage 13 (48.1%) 1 (10%)
Infection 7 (25.9%) 8 (80%)
Differentiation syndrome 5 (18.5%)
Respiratory failure 1 (10%)
Thrombosis 1 (3.7%)
All 27 10
Empty cells mean that no event was detected.
Table 4. Logistic regression analysis for CR
Variable
Univariable Multivariable
OR 95% CI P value OR 95% CI P value
WBC* 0.98 0.96 0.99 .0005 0.98 0.96 0.99 .01
Coagulopathy, yes vs no 0.43 0.16 1.13 .09 0.27 0.08 0.89 .03
Creatinine, abnormal vs normal* 0.21 0.06 0.72 .01 0.28 0.06 1.32 .11
Albumin† 6.57 2.71 15.94 ,.0001 4.60 1.74 12.15 .002
OR, odds ratio.
*The relationship between creatinine levels and CR was quadratic, thus we categorized the patients as presenting normal values (0.5 # creatinine #1.4 mg/dL) or not.
†Analyzed as continuous variables because the linearity assumption for these variables was met.
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and reliability of the immunoﬂuorescence staining technique in the
context of developing countries. Due to the short time required to
conﬁrm diagnosis, use of the immunoﬂuorescence technique
allowed the rapid initiation of daunorubicin and supportive
measures, most likely contributing to reduced early mortality.
There is a disparity between reported outcomes, particularly in
the hemorrhagic death rates in clinical trials as compared with
population-based studies. Park et al34 analyzed the outcomes of
1400 patients with APL recorded in 13 cancer registries in the
National Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) program between 1992 and 2007. They reported
a death rate within 1 month of APL diagnosis of 17.3% and 3-year
OS of 65.7%. This rate did not change when different time periods
were compared. Lehmann et al35 studied 105 patients with APL
registered in the population-based Swedish Adult Acute Leukemia
Registry between 1997 and 2006 and reported death rates of 29%
and 26% within 30 and 14 days of diagnosis, respectively. At 6.4
years median follow-up, 62% of patients were alive. Both
American and Swedish studies indicate that the incidence of early
death is higher in the “real world” than in clinical trials because
the latter fail to account for patients who die of hemorrhagic
complications before registration. Comparison between the 2
aforementioned studies and the IC-APL study is hampered by the
small number of patients accrued in the latter study relative to the
large population and the lack of population-based data in the 4
involved countries. However, the reduction in deaths caused by
hemorrhage during induction after the implementation of IC-APL
suggests that medical education and rapid diagnosis with prompt
measures to counteract APL-associated coagulopathy are important
mainstays in decreasing early mortality.
The 2-year DFS and OS of patients enrolled in the IC-APL
study were comparable to those from trials conducted in developed
countries, despite the relatively high proportion of high-risk
patients.3-5,7,8,36 Although the CIR was signiﬁcantly higher in
patients presenting with WBC .10 3 109/L compared with the
low- and intermediate-risk groups, the overall rates were comparable
to those reported in trials conducted in developed countries
(supplemental Table 6).3,5,8,9,11 However, the NRM in the high-
risk group (10.9%) was higher than that reported in recent trials.3,8
In the present study, arsenic trioxide (ATO) was not included in
the treatment protocol because of its high cost in the involved
countries. ATO is not reimbursed by the public health systems in
Brazil, Uruguay, and Mexico as front-line therapy for APL. The
experience with ATO as a single agent reported in India, China,
and Iran demonstrates that this agent is highly effective and
treatment has acceptable toxicity.37-40 Moreover, in the North
American Leukemia Intergroup Study C9710, the addition of ATO
to standard therapy with ATRA plus daunorubicin as consolidation
resulted in signiﬁcant improvement in the DSF and EFS of adult
patients in all risk groups.11
Monitoring of minimal residual disease using RT-PCR for the
PML/RARA rearrangement showed that the IC-APL treatment
schedule achieved molecular remission in the majority of patients.
This is in accordance with results obtained with ATRA and
anthracycline-based protocols used in developed countries.41-43
Four of the 9 relapses (44.4%) were molecular, which is in
agreement with studies that used this technique.44 However, a
higher sensitivity of test has been reported in trials using real-time
quantitative polymerase chain reaction assays.42,43 Although this
Figure 2. (A) OS and DSF and (B) cumulative incidence of relapse and
cumulative incidence of nonrelapse mortality rates among patients with
acute promyelocytic leukemia treated in the IC-APL study.
Table 5. Outcome of APL patients in the IC-APL 2006 trial
Patient
CIR CI of NRM DFS EFS OS
N 2-y % (95% CI) N 2-y % (95% CI) N 2-y % (95% CI) N 2-y % (95% CI) N 2-y % (95% CI)
All patients 153 4.5 (1.8, 9.2) 153 5.3 (2.4, 9.6) 153 91 (86, 95) 183 77 (70, 83) 183 80 (73-85)
Low risk 24 0 24 8.9 (1.4, 25.1) 24 91 (69, 98) 30 79 (59, 90) 30 79 (59, 90)
Intermediate risk 83 1.2 (0.1, 5.9) 83 1.2 (0.1, 5.9) 83 98 (91, 99) 95 86 (78, 92) 95 87 (79, 93)
High risk 46 14.1 (4.6, 28.7) 46 10.9 (3.9, 21.8) 46 77 (59, 88) 58 59 (45, 72) 58 67 (53, 76)
P value 0.08 0.04 0.009 0.005 0.01
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frequency is low, we consider it worthwhile to perform molecular
monitoring based on the results reported with the preemptive
treatment with ATO of these patients.43 The 4 patients who had
molecular relapses (all during maintenance) were treated with
alternative regimens (2 with ATO and 2 with polychemotherapy
and ATRA) and achieved a second remission; however, our sample
size was too small to draw any conclusions. We opted to perform
the molecular tests exclusively on BM aspirates, following the
recommendation of the European LeukemiaNet.1 Importantly, our
experience demonstrates the feasibility of molecular monitoring
in developing countries through the establishment of national
reference laboratories.
The treatment of acute leukemia and APL requires speciﬁc
expertise and skills. The results presented here demonstrate that it
is possible to improve the prognosis of severe and rapidly fatal
malignancies, such as APL, in developing countries by international
collaboration at relatively low cost. The dissemination of essential
clinical management guidelines and increased awareness of APL,
coupled with a simple method for rapid diagnosis and the
implementation of Internet tools for the exchange of clinical
expertise, was effective in abolishing differences in treatment
outcomes between developed and developing countries. With the
aim of transferring the experience gained with clinical networking
in the IC-APL to another more challenging leukemia subset,
a consortium for the treatment of acute myeloid leukemia has
recently been initiated.
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